Interim Results of the Phase 2b/3 GALAXY Trial to be Presented at the Fifth
Asia Pacific Lung Cancer Conference
LEXINGTON, Mass. -- November 26, 2012
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that interim
results of the Phase 2b portion of the GALAXY program will be presented on
November 28, 2012 at 12:15 p.m. (JST) during the “Highlights of Oral
Presentations” session at the Fifth Asia Pacific Lung Cancer Conference (APLCC
2012) in Fukuoka City, Japan. Dr. Christian Manegold, Professor of Medicine
and head of Interdisciplinary Thoracic Oncology in the Department of Surgery
at University Medical Center Mannheim, Heidelberg University, in Mannheim,
Germany, will present the data, focusing on prior results highlighted at the
2012 Congress of the European Society for Medical Oncology (ESMO) last
The 800-patient Phase 2b/3 GALAXY program is designed to compare single agent
docetaxel versus docetaxel plus ganetespib, a potent and selective Hsp90
inhibitor, as second-line treatment of advanced non-small cell lung cancer.
Ganetespib is a potent inhibitor of heat shock protein 90 (Hsp90) that is
structurally unrelated to first-generation, ansamycin-related Hsp90
inhibitors. In preclinical experiments, ganetespib has shown activity in
multiple tumor models both as a single agent and in combination with certain
widely used cancer agents. Company-sponsored clinical trials with ganetespib
include 1) the GALAXY Phase 2b/3 program evaluating ganetespib in combination
with docetaxel as second-line treatment of non-small cell lung cancer (NSCLC),
2) the CHIARA Phase 2 trial evaluating ganetespib monotherapy in ALK+ NSCLC,
and 3) the ENCHANT Phase 2 trial evaluating ganetespib as first-line treatment
for HER2+ and triple-negative metastatic breast cancer. In addition,
ganetespib is being evaluated in investigator-sponsored trials including lung,
breast, prostate, gastric, pancreatic, and colorectal cancers as well as
ocular melanoma, acute myeloid leukemia and multiple myeloma. Information on
these trials can be found at www.clinicaltrials.gov.
About the GALAXY Trials™
The GALAXY (Ganetespib Assessment in Lung cAncer with docetaXel) program
consists of two randomized trials comparing the combination of ganetespib and
docetaxel versus docetaxel alone in patients with Stage IIIB/IV NSCLC who have
received one prior systemic therapy: a 300-patient Phase 2b study to determine
the patient population most likely to derive benefit from ganetespib, and a
500-patient Phase 3 pivotal trial enriched for this identified population.
More information about the GALAXY trials can be found at
Hsp90 is a molecular chaperone required for the proper folding and activation
of many cancer-promoting proteins, and is recognized as a key facilitator of
cancer cell growth and survival. Many of the “client proteins” of Hsp90 – such
as ALK, AKT, BCR-ABL, BRAF, KIT, MET, EGFR, FLT3, HER2, HIF-1alpha, PDGFRA,
VEGFR are the targets of clinically validated cancer drugs. In preclinical
studies, inhibiting Hsp90 causes the degradation of multiple client proteins
and leads to cancer cell death.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on
discovering, developing, and commercializing small molecule drugs to extend
and enhance the lives of patients with severe medical conditions, including
cancer and chronic inflammatory diseases. Synta has a unique chemical compound
library, an integrated discovery engine, and a diverse pipeline of clinical-
and preclinical-stage drug candidates with distinct mechanisms of action and
novel chemical structures. All Synta drug candidates were invented by Synta
scientists using our compound library and discovery capabilities. For more
information, please visit www.syntapharma.com.
Synta Pharmaceuticals Corp.
George Farmer, 781-541-7125
Press spacebar to pause and continue. Press esc to stop.